Effect of Adjunct Balloon Dilation after Long Everolimus-eluting Stent Deployment on Major Adverse Cardiac Events
Why the study?
Does post-stent adjunct balloon dilation reduce major adverse cardiac events in patients treated with long everolimus-eluting stents?
Population
1,672 patients treated with long everolimus-eluting stents drawn from 2 randomized trials, analyzed as 595…
Comparison
Post-stent adjunct balloon dilation vs No post-stent adjunct balloon dilation
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
May not warrant routine adjunct balloon dilation after long EES; leaves open potential subgroup benefits in stable angina or small vessels.
Structured PICO
Does post-stent adjunct balloon dilation reduce major adverse cardiac events in patients treated with long everolimus-eluting stents?
P
Population
1,672 patients treated with long everolimus-eluting stents (EES) drawn from 2 randomized trials, analyzed as 595 propensity score-matched pairs.
I
Intervention
Post-stent adjunct balloon dilation
C
Comparator
No post-stent adjunct balloon dilation
O
Outcome
Major adverse cardiac events (MACE), defined as a composite of cardiac death, myocardial infarction, and target-lesion revascularization (TLR) at 1 yearcomposite
Routine adjunct balloon dilation after long everolimus-eluting stent deployment does not reduce MACE at 1 year overall, though it may offer benefit in patients with stable angina or small vessel diameters.
Cite This Study
Hong et al. (2017) studied this question.